Payment overview · 2025
General Payments
$314.58
18 reported records · 8 companies
Healthcare provider profile · identity verified
Matthew J King, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COOKEVILLE, TN · NPI 1932101284
Verified facts
What the public records show
CMS Open Payments records show Matthew J King, M.D. received $314.58 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.05 | 22.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.45 | 21.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.83 | 16.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.92 | 10.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.02 | 9.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.23 | 8.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.08 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.00 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.58 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 154 |
| Lisinopril | Lisinopril | 393 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 118 |
| Gabapentin | Gabapentin | 352 | 82 |
| Prednisone | Prednisone | 316 | 195 |
| Metformin Hcl | Metformin Hcl | 307 | 106 |
| Furosemide | Furosemide | 303 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 89 |
| Omeprazole | Omeprazole | 238 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 71 |
| Montelukast Sodium | Montelukast Sodium | 190 | 61 |
| Losartan Potassium | Losartan Potassium | 179 | 63 |
| Azithromycin | Azithromycin | 169 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 54 |
| Carvedilol | Carvedilol | 151 | 47 |
| Simvastatin | Simvastatin | 139 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 128 | 35 |
| Sertraline Hcl | Sertraline Hcl | 125 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 44 |
| Famotidine | Famotidine | 117 | 39 |
| Trazodone Hcl | Trazodone Hcl | 114 | 38 |
| Ozempic | Semaglutide | 105 | 23 |
| Allopurinol | Allopurinol | 104 | 36 |
| Spironolactone | Spironolactone | 104 | 36 |
| Jardiance | Empagliflozin | 102 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 101 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 39 |
| Meloxicam | Meloxicam | 99 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 95 | 72 |
| Tramadol Hcl | Tramadol Hcl | 94 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 41 |
| Celecoxib | Celecoxib | 92 | 28 |
| Atenolol | Atenolol | 91 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 11 |
| Metformin Hcl Er | Metformin Hcl | 79 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 25 |
| Eliquis | Apixaban | 76 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 21 |
| Potassium Chloride | Potassium Chloride | 71 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 20 |
| Glimepiride | Glimepiride | 66 | 21 |
| Xarelto | Rivaroxaban | 62 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | 19 |
| Benazepril Hcl | Benazepril Hcl | 53 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 34 |
| Donepezil Hcl | Donepezil Hcl | 50 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 22 |
| Finasteride | Finasteride | 46 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 11 |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 22 |
| Lovastatin | Lovastatin | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 29 |
| Buspirone Hcl | Buspirone Hcl | 41 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 15 |
| Ondansetron Odt | Ondansetron | 41 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | 16 |
| Cephalexin | Cephalexin | 38 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 17 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Estradiol | Estradiol | 35 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Cefdinir | Cefdinir | 33 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 14 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | 16 |
| Glipizide | Glipizide | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | 20 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metolazone | Metolazone | 18 | 11 |
| Nystatin | Nystatin | 18 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.58 · 18 records | Amgen Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, EVENITY, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error